Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2016 > Teva Secures European Approval of Trisenox® for First Line Treatment of Low to Intermediate Risk Acute Promyelocytic Leukemia (APL)

Teva Secures European Approval of Trisenox® for First Line Treatment of Low to Intermediate Risk Acute Promyelocytic Leukemia (APL)

Read also

Myeloma
Myeloma
Myeloma treatment HDP-101 put on FDA fast track
Evotec Announces Progress
Evotec Announces Progress
Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb
Evotec Announces Progress
Evotec Announces Progress
Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb
Tylenol (paracetamol)
Tylenol (paracetamol)
Tylenol (paracetamol) fights autism claims, slams proposed FDA warning label as 'unsupported' by science
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand